Majid Kalani, MD, PhD
Consultant Interventional Cardiologist
Department of Cardiology
Danderyd University Hospital &
Dr. Kalani is Senior Consultant Interventional Cardiologist at Danderyd University Hospital in Stockholm, Sweden, and Director of Cardiac Cath Lab at Ygia Polyclinic in Cyprus. Dr. Kalani completed his PhD in the field of Cardiovascular Medicine and Diabetes Microangiopathy, and currently he is Senior Researcher at Karolinska Institute in Stockholm leading several research projects in the field of diabetes macro- and microangiopathy, and myocardial perfusion in interventional cardiology.
His interests include: Interventional cardiology, Permanent pacemaker implantation, General cardiology, Cardiothoracic intensive care, Emergency medicine especially internal medicine at the ER.
BOARDS AND COMMITTEES
• Member of the Education Committee of the Swedish Society of Cardiology – August 2002 to 2005
• Member of the Swedish Society of Angiology – January 2003 to 2008
1. Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care. 1999; 22: 147-151.
2. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy of diabetic foot ulcers – long term follow up. Journal of Diabetes and Its Complications. 2002; 16: 153-158.
3. Kalani M, Apelqvist J, Blomback M, et al. Effect of Dalteparin on Outcome of Chronic Foot Ulcers in Diabetic Patients with Peripheral Arterial Occlusive Disease. A prospective, randomized, double-blind, placebo-controlled study. Diabetes Care. 2003; 26: 2575-2580.
4. Jorneskog G, Kalani M, Kuhl J, et al. Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. Diabetes Care. 2005; 28(6): 1495-7.
5. Kalani M, Silveira A, Blomback M, et al. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res. 2007; 120(5): 653-61.
6. Settergren M, Pernow J, Brismar K, Jorneskog G, Kalani M. Endothelin-A receptor blockade improves nutritive skin capillary circulation in patients with type 2 diabetes and albuminuria. J Vasc Res. 2008; 45: 295-302. doi: 10.1159/000113601.
7. Kalani M, Pernow J, Bragd J, Jorneskog G. Improved peripheral perfusion during endothelin-A receptor blockade in patients with type 2 diabetes and critical limb ischemia. Diabetes Care. 2008;3 1(7): e56 doi: 10.2337/dc08-0409.
8. Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vascular Health and Risk Management. 2008: 4(5): 1061-1068.
9. Skeppholm M, Kallner A, Kalani M, Jorneskog G, Blomback M, Wallén NH. ADAMTS-13 and von Willebrand factor concentrations in patients with diabetes mellitus. Blood Coagulation & Fibrinolysis, Blood Coagul Fibrinolysis. 2009; 20(8): 619-26. doi: 10.1097/MBC.0b013e32832da183.
10. Settergren M, BOhm F, Rydén L, Pernow J, Kalani M. Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycemia and coronary artery disease. J Intern Med. 2009; 266(5): 492-8. doi: 10.1111/j.1365-2796.2009.02128.x.
11. Papadogeorgos N, Bengtsson M, Kalani M. Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes. Vasc Health Risk Manag. 2009; 5: 893-9.
12. Papadogeorgos NO, Bengtsson M, Kalani M . Severely impaired microvascular function in diabetic patients with acute coronary syndrome. Vasc Health Risk Manag. 2009; 5: 893-9.
13. Kafian S, Mobarrez F, Kalani M, Wallén H, Samad BA. Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry. Scand J Clin Lab Invest. 2011; 71(8): 637-40. doi: 10.3109/00365513.2011.604731
14. Jarnert C, Kalani M, Rydén L, BOhm F. Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: A report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study. Diab Vasc Dis Res. 2012;
15. Torffvit O, Kalani M, Apelqvist J, et al. Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes. Biochem Res Int. 2012; 2012: 480529. doi: 10.1155/2012/480529.